The EGFR T790M mutation is a well-characterised gatekeeper alteration in which threonine at position 790 is replaced by methionine, conferring resistance to first-generation EGFR tyrosine-kinase inhibitors such as gefitinib and erlotinib. It accounts for a substantial share of acquired resistance in EGFR-mutant lung cancer. Because the third-generation inhibitor osimertinib was developed and approved alongside a companion diagnostic to detect this substitution, testing sits at the intersection of molecular science and regulatory oversight. Accurate detection therefore determines not only diagnosis but also which targeted therapy a patient may receive.
When resistance emerges, the T790M clone may exist alongside sensitive tumor cells and can represent only a minor fraction of the total tumor burden. In plasma-based liquid biopsy, tumor DNA is diluted among normal cell-free DNA, so the variant can appear at very low allele frequency. An assay with limited analytical sensitivity might miss it, leading to a false-negative result and a missed opportunity for targeted therapy. Ultra-sensitive methods are therefore valued for detecting low-abundance variants. Repeated testing over time can also track whether the resistant clone expands or shrinks during treatment.
In major markets, tests that guide targeted therapy are subject to in vitro diagnostic regulations and often require validation as companion or supplementary diagnostics. Laboratories must demonstrate analytical sensitivity and specificity, establish validated workflows, and operate under recognised quality systems and accreditation. Pre-analytical factors, sample type, collection, and storage, are part of that quality chain, because degraded or improperly handled specimens compromise even the best assay.
Tissue biopsy remains a reference standard but is invasive and not always feasible when disease progresses. Liquid biopsy with circulating tumor DNA offers a less invasive alternative and can capture tumor heterogeneity, yet it demands rigorous assay validation to be trustworthy. Regulatory expectations increasingly recognise both routes provided the test meets performance claims. Buyers of such testing services should confirm the assay's approved indications, validation data, and reporting standards.
Q: Why is T790M testing tied to a companion diagnostic? A: Osimertinib was approved with a diagnostic to confirm the T790M substitution, so testing is required to select eligible patients.
Q: Why does the assay need ultra-high sensitivity? A: The resistance variant can be a minor clone and appear at low allele frequency in plasma, risking false negatives with less sensitive tests.
Q: Is liquid biopsy as reliable as tissue? A: It is less invasive and captures heterogeneity, but requires strict validation; tissue remains a reference when available.
Q: What quality checks matter for such tests? A: Demonstrated analytical sensitivity and specificity, accredited lab processes, validated pre-analytical handling, and clear reporting standards.
The EGFR T790M mutation is a well-characterised gatekeeper alteration in which threonine at position 790 is replaced by methionine, conferring resistance to first-generation EGFR tyrosine-kinase inhibitors such as gefitinib and erlotinib. It accounts for a substantial share of acquired resistance in EGFR-mutant lung cancer. Because the third-generation inhibitor osimertinib was developed and approved alongside a companion diagnostic to detect this substitution, testing sits at the intersection of molecular science and regulatory oversight. Accurate detection therefore determines not only diagnosis but also which targeted therapy a patient may receive.
When resistance emerges, the T790M clone may exist alongside sensitive tumor cells and can represent only a minor fraction of the total tumor burden. In plasma-based liquid biopsy, tumor DNA is diluted among normal cell-free DNA, so the variant can appear at very low allele frequency. An assay with limited analytical sensitivity might miss it, leading to a false-negative result and a missed opportunity for targeted therapy. Ultra-sensitive methods are therefore valued for detecting low-abundance variants. Repeated testing over time can also track whether the resistant clone expands or shrinks during treatment.
In major markets, tests that guide targeted therapy are subject to in vitro diagnostic regulations and often require validation as companion or supplementary diagnostics. Laboratories must demonstrate analytical sensitivity and specificity, establish validated workflows, and operate under recognised quality systems and accreditation. Pre-analytical factors, sample type, collection, and storage, are part of that quality chain, because degraded or improperly handled specimens compromise even the best assay.
Tissue biopsy remains a reference standard but is invasive and not always feasible when disease progresses. Liquid biopsy with circulating tumor DNA offers a less invasive alternative and can capture tumor heterogeneity, yet it demands rigorous assay validation to be trustworthy. Regulatory expectations increasingly recognise both routes provided the test meets performance claims. Buyers of such testing services should confirm the assay's approved indications, validation data, and reporting standards.
Q: Why is T790M testing tied to a companion diagnostic? A: Osimertinib was approved with a diagnostic to confirm the T790M substitution, so testing is required to select eligible patients.
Q: Why does the assay need ultra-high sensitivity? A: The resistance variant can be a minor clone and appear at low allele frequency in plasma, risking false negatives with less sensitive tests.
Q: Is liquid biopsy as reliable as tissue? A: It is less invasive and captures heterogeneity, but requires strict validation; tissue remains a reference when available.
Q: What quality checks matter for such tests? A: Demonstrated analytical sensitivity and specificity, accredited lab processes, validated pre-analytical handling, and clear reporting standards.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
